Axel Hauschild, MD - Advancing Outcomes in Surgically Resectable Cutaneous Squamous Cell Carcinoma: Carving New Paths Forward With Immunotherapies

Please visit answersincme.com/KDX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the use of neoadjuvant immunotherapies in the treatment of surgically resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the rationale for using neoadjuvant immunotherapies for patients with surgically resectable CSCC; Review the latest evidence on the efficacy and safety of emerging neoadjuvant immunotherapies for patients with surgically resectable CSCC; and Outline clinical strategies to optimize the therapeutic management of surgically resectable CSCC for patients who would be appropriate candidates for neoadjuvant immunotherapies.